Detection of Placental-Type Alkaline Phosphatase in Ovarian Cancer
Author Information
Author(s): I.W. McDicken, P.J. McLaughlin, P.M. Tromans, D.M. Luesley, P.M. Johnson
Primary Institution: University of Liverpool
Hypothesis
Can placental-type alkaline phosphatase (PLAP) be effectively detected in ovarian cancer patients using a specific monoclonal antibody?
Conclusion
PLAP was detected in the serum and tissue of a significant proportion of patients with ovarian tumours, indicating its potential as a marker for ovarian cancer.
Supporting Evidence
- PLAP was detected in over 30% of sera from ovarian cancer patients.
- Circulating PLAP levels did not correlate with the stage of disease.
- Immunohistology showed heterogeneity of PLAP localization in different tumors.
Takeaway
Doctors can find a special protein called PLAP in the blood of some women with ovarian cancer, which helps them know if there is a tumor.
Methodology
The study used a monoclonal antibody to detect PLAP in serum, tissue extracts, and tumor sections from ovarian cancer patients.
Limitations
The study did not find a significant correlation between circulating PLAP levels and clinical staging of the disease.
Participant Demographics
67 patients with malignant ovarian tumors and 22 with benign tumors.
Statistical Information
Statistical Significance
p>0.05
Want to read the original?
Access the complete publication on the publisher's website